Plain-English translation of NCT06251778 on ClinicalTrials.gov ↗ · Source last updated · Translation generated · How we translate trials
Read our Amyloidosis research guide →This is a real-world study of patients with transthyretin amyloidosis—a rare condition where abnormal proteins build up in the heart—who are taking tafamidis to slow disease progression. Researchers want to carefully monitor how the medication works and how your heart responds to it, especially watching for any changes in heart rhythm. The study will help doctors better understand this treatment's safety and effectiveness in everyday clinical practice.
Transthyretin amyloidosis can cause serious heart rhythm problems, and doctors need better information about how this medication affects those risks over time. By tracking patients closely, researchers can identify early warning signs and help doctors manage care more effectively.
You likely qualify if…
You likely don't qualify if…
You will visit the clinic before starting the medication and then every six months for the duration of the study. At each visit, your doctor will perform a physical exam, review how you're doing, and likely order heart rhythm tests (such as an electrocardiogram or Holter monitoring) to check for any changes. The study team will track your heart rhythm, how much diuretic medication you may need, and your overall response to treatment—all as part of your regular medical care.
AI-generated summary from trial data · Jun 10, 2026 · Not medical advice
Italy